Arrowhead Pharmaceuticals, Inc.

393 articles with Arrowhead Pharmaceuticals, Inc.

• Arrowhead Pharmaceuticals Reports Inducement Grants

  9/24/2020

  Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 11, 2020, the Compensation Committee of the Board of Directors approved “inducement” grants to 30 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option grants entitle employees, in aggregate, to purchase up to 173,000 shares of common stock and receive

• 

  Clinical Catch-Up: September 14-18

  9/21/2020

  It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.

• Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment

  9/16/2020

  - Up to 97% reduction in intra-hepatic Z-AAT polymer - Up to 95% reduction in intra-hepatic total Z-AAT burden - Up to 66% and 58% reduction in circulating ALT and GGT levels respectively - Up to 26% improvement in FibroScan values PASADENA, Calif.--( BUSINESS WIRE )-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 24-week liver biopsy results in four subjects from AROAAT2002, an open-label Phase 2 clinica

• Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences

  9/8/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Citi’s 15th Annual BioPharma Virtual Conference September 9, 2020 – Arrowhead management will participate in investor meetings Baird's 2020 Global Healthcare Conference September 10, 2020, 2:00 p.m. EDT – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will

• Arrowhead Pharmaceuticals Appoints Oye Olukotun to Board of Directors

  9/8/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Oye Olukotun, M.D., MPH, as an independent director of the company, with a term beginning effective September 1, 2020. Douglass Given, M.D., Ph.D., Chairman of the Board of Arrowhead, said, “Oye is a senior physician executive, with deep scientific and clinical development ex

• Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020

  8/31/2020

  Arrowhead Pharmaceuticals Inc. announced the presentation of positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III being developed as a treatment for patients with hypertriglyceridemia, and ARO-ANG3 targeting angiopoietin like protein 3 being developed as a treatment for mixed dyslipidemias.

• Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress

  8/28/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of Phase 2 clinical data from the AROHBV1001 phase 1/2 study on a double combination of JNJ-3989 (formerly ARO-HBV) and a nucleos(t)ide analog (NA) with collaborator Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson. The data are being presented in an oral presentation at The Digital Internat

• Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

  8/18/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC).

• Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences

  8/18/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

• Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis

  8/11/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF), which is a rare disease caused by genetic mutations that lead to progressive deterioration in lung function due to poor clearance o

• Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results

  8/5/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2020.

• Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890

  7/29/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a Phase 2 clinical study. The study is evaluating the efficacy, safety, and tolerability of AMG 890 in subjects with elevated levels of lipoprotein (a) (Lp(a)). Emerging research has shown that elevated l

• Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis

  7/28/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a key opinion leader webinar today at 12:00 PM EDT on ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF). The webinar features a presentation by Marcus Mall, M.D., professor and director of the Department of Pediatric Pulmonology and Immunology at The Charité Univer

• Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) - July 24, 2020

  7/24/2020

  Arrowhead Pharmaceuticals Inc. announced that as an inducement to entering into employment with the Company, on June 18, 2020, the Compensation Committee of the Board of Directors approved "inducement" grants to 25 new employees under Rule 5635 of the NASDAQ Marketplace Rules.

• Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis

  7/9/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on July 28, 2020, at 12:00 p.m. EDT it will host a key opinion leader webinar on ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF). The webinar will feature a presentation by Marcus Mall, M.D., Professor and Director of the Department of Pediatric P

• Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Third Quarter Results

  7/8/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 5, 2020, at 4:30 p.m. EDT to discuss its financial results for the fiscal third quarter ended June 30, 2020.

• Arrowhead Pharmaceuticals to Participate in Upcoming June 2020 Conferences

  5/28/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Virtual Healthcare Conference – June 2-4, 2020 June 4, 2:00 p.m. EDT – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation Goldman Sachs 41st Annual Global Healthcare Conference – June 9-11, 2020

• Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results

  5/7/2020

  Arrowhead Pharmaceuticals Inc. announced financial results for its fiscal second quarter ended March 31, 2020. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.

• Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences

  5/1/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

• Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given

  5/1/2020

  Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the retirement of Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, which was previously planned and disclosed, after a more than 30-year career in biotechnology and pharmaceutical research, development, and sales and marketing.